Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

BACKGROUND & AIMS Assay of altered DNA exfoliated into stool represents an intriguing approach to screen for colorectal neoplasia, but multiple markers must be targeted because of genetic heterogeneity. We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without. METHODS Freezer-archived stools were analyzed in blinded fashion from 22 patients with colorectal cancer, 11 with adenomas > or =1 cm, and 28 with endoscopically normal colons. After isolation of human DNA from stool by sequence-specific hybrid capture, assay targets included point mutations at any of 15 sites on K-ras, p53, and APC genes; Bat-26, a microsatellite instability marker; and highly amplifiable DNA. RESULTS Analyzable human DNA was recovered from all stools. Sensitivity was 91% (95% confidence interval, 71%-99%) for cancer and 82% (48%-98%) for adenomas > or =1 cm with a specificity of 93% (76%-99%). Excluding K-ras from the panel, sensitivities for cancer were unchanged but decreased slightly for adenomas to 73% (39%-94%), while specificity increased to 100% (88%-100%). CONCLUSIONS Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia. Larger clinical investigations are indicated.

[1]  J. Jett,et al.  Universal detection of aerodigestive cancers by assay of nonapoptotic human DNA in stool , 2000 .

[2]  D. Ahlquist,et al.  Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. , 2000, Human pathology.

[3]  C. Adebamowo,et al.  Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. , 1999, The American journal of pathology.

[4]  M. Leppert,et al.  BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. , 1999, The American journal of pathology.

[5]  S. Pääbo,et al.  Molecular coproscopy: dung and diet of the extinct ground sloth Nothrotheriops shastensis. , 1998, Science.

[6]  D. Schaid,et al.  Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. , 1998, Cancer research.

[7]  Simon Jb.  Fecal occult blood testing: clinical value and limitations. , 1998 .

[8]  C. Boland,et al.  Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. , 1998, Cancer detection and prevention.

[9]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[10]  J. Weissfeld,et al.  K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. , 1997, Cancer research.

[11]  M. Slattery,et al.  Microsatellite instability in colorectal adenomas. , 1997, Gastroenterology.

[12]  D. Ahlquist.  Fecal occult blood testing for colorectal cancer. Can we afford to do this? , 1997, Gastroenterology clinics of North America.

[13]  G. Thomas,et al.  BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. , 1997, Cancer research.

[14]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[15]  G. Curigliano,et al.  Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces , 1996, Diseases of the colon and rectum.

[16]  K. Koretz,et al.  Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. , 1996, Gastroenterology.

[17]  C. Wagener,et al.  Detection of K‐ras mutations in stools of patients with colorectal cancer by mutant‐enriched PCR , 1996, International journal of cancer.

[18]  A. Rebecchi,et al.  Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. , 1996, Gastroenterology.

[19]  D. Ahlquist,et al.  Stool markers for colorectal cancer screening: future considerations. , 1996, Digestive diseases.

[20]  S. Tsujitani,et al.  Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma , 1996 .

[21]  T. Kanematsu,et al.  Mutations of the p53 gene in the stool of patients with resectable colorectal cancer , 1996, Cancer.

[22]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[23]  P. Pasricha,et al.  Inhibition of apoptosis during development of colorectal cancer. , 1995, Cancer research.

[24]  H. Ohta,et al.  Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). , 1995, Oncogene.

[25]  H. Esumi,et al.  Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. , 1995, Gastroenterology.

[26]  W. Bodmer,et al.  Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. , 1995, Gut.

[27]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[28]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[29]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[30]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[31]  H. Wieand,et al.  Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. , 1993, JAMA.

[32]  P. Quirke,et al.  Molecular biology of colorectal neoplasia. , 1993, Gut.

[33]  G. Chenevix-Trench,et al.  Genomic instability occurs in colorectal carcinomas but not in adenomas , 1993, Human mutation.

[34]  S. Sen.  PROGRAMMED CELL DEATH: CONCEPT, MECHANISM AND CONTROL , 1992, Biological reviews of the Cambridge Philosophical Society.

[35]  M. Seki,et al.  Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. , 1992, Cancer research.

[36]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[37]  K Kontula,et al.  A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. , 1990, Genomics.

[38]  D. Ransohoff,et al.  Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity. , 1990, JAMA.

[39]  R. Yolken,et al.  Removal of inhibitory substances from human fecal specimens for detection of group A rotaviruses by reverse transcriptase and polymerase chain reactions , 1990, Journal of clinical microbiology.

[40]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[41]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[42]  D. Ahlquist,et al.  A stool collection device: the first step in occult blood testing. , 1988, Annals of internal medicine.

[43]  J. W. Frank.  Occult-blood screening for colorectal carcinoma: the yield and the costs. , 1985, American journal of preventive medicine.

[44]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.

[45]  T. Allen,et al.  Ultrastructure of cell loss in intestinal mucosa. , 1977, Journal of ultrastructure research.